Danaher (NYSE:DHR) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Danaher (NYSE:DHR – Get Rating) in a report issued on Thursday. The brokerage set a “buy” rating on the conglomerate’s stock.

Several other equities research analysts have also commented on the company. Credit Suisse Group lowered Danaher from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $315.00 to $300.00 in a research note on Thursday, January 5th. Cowen dropped their price target on Danaher from $340.00 to $320.00 and set an “outperform” rating for the company in a research note on Wednesday, January 25th. Deutsche Bank Aktiengesellschaft initiated coverage on Danaher in a research note on Tuesday, December 13th. They issued a “buy” rating and a $310.00 target price for the company. Barclays increased their target price on Danaher from $277.00 to $290.00 and gave the company an “overweight” rating in a research note on Tuesday, January 24th. Finally, Robert W. Baird lowered their target price on Danaher from $321.00 to $309.00 in a research note on Wednesday, January 25th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $310.29.

Danaher Stock Performance

NYSE DHR opened at $242.11 on Thursday. The company has a market capitalization of $176.40 billion, a PE ratio of 25.09, a price-to-earnings-growth ratio of 1.97 and a beta of 0.80. The company has a current ratio of 1.89, a quick ratio of 1.52 and a debt-to-equity ratio of 0.39. The business’s 50-day moving average price is $258.79 and its 200 day moving average price is $262.73. Danaher has a twelve month low of $233.71 and a twelve month high of $303.82.

Danaher (NYSE:DHR – Get Rating) last announced its quarterly earnings results on Tuesday, January 24th. The conglomerate reported $2.87 EPS for the quarter, topping the consensus estimate of $2.46 by $0.41. The company had revenue of $8.37 billion during the quarter, compared to analyst estimates of $7.90 billion. Danaher had a return on equity of 17.97% and a net margin of 22.91%. The firm’s revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.69 earnings per share. On average, research analysts predict that Danaher will post 10.14 earnings per share for the current year.

Insider Activity at Danaher

In related news, Director Raymond C. Stevens sold 8,410 shares of the stock in a transaction dated Wednesday, January 25th. The stock was sold at an average price of $264.27, for a total value of $2,222,510.70. Following the completion of the transaction, the director now owns 8,394 shares of the company’s stock, valued at $2,218,282.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 11.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Freedom Wealth Alliance LLC bought a new position in Danaher during the 4th quarter worth approximately $27,000. Chelsea Counsel Co. bought a new position in Danaher during the 4th quarter worth approximately $27,000. My Personal CFO LLC bought a new stake in shares of Danaher in the 4th quarter worth approximately $29,000. Private Ocean LLC lifted its holdings in shares of Danaher by 1,485.7% in the 4th quarter. Private Ocean LLC now owns 111 shares of the conglomerate’s stock worth $29,000 after purchasing an additional 104 shares during the last quarter. Finally, Moisand Fitzgerald Tamayo LLC lifted its holdings in shares of Danaher by 5,850.0% in the 3rd quarter. Moisand Fitzgerald Tamayo LLC now owns 119 shares of the conglomerate’s stock worth $31,000 after purchasing an additional 117 shares during the last quarter. Institutional investors own 77.26% of the company’s stock.

About Danaher

(Get Rating)

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services.